PD-1/PD-L1 interactions assist tumor cells in immune evasion and impact CAR-T therapy by reducing T cell glycolysis, impairing T cell effector functions, and limiting glucose availability for T cells (142). The gene discussed is CD274; the disease is neoplasm.